(Q43253477)

English

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.

scientific article published in October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Richard A. Larson

9

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1

object named as

John C Byrd

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

4

object named as

David Hurd

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

author name string

Bercedis L Peterson

2

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Kanti R Rai

3

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Raymond Hohl

5

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Michael C Perry

6

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Jon Gockerman

7

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Sreenivasa Nattam

8

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

publication date

1 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

1589-1596

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190903150839

21 January 2018

Identifiers

10.1080/10428190903150839

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43253477&oldid=1782267392"